Synthesis, characterization and cytotoxicity of poly(ethylene glycol)-graft-trimethyl chitosan block copolymers

被引:241
作者
Mao, SR
Shuai, XT
Unger, F
Wittmar, M
Xie, XL
Kissel, T
机构
[1] Univ Marburg, Dept Pharmaceut & Biopharm, D-35032 Marburg, Germany
[2] Shenyang Pharmaceut Univ, Dept Pharm, Shenyang 110016, Peoples R China
[3] Univ Marburg, Dept Chem, D-35032 Marburg, Germany
关键词
trimethyl chitosan; PEGylation; copolymer; in vitro cytotoxicity; MTT assay; LDH assay;
D O I
10.1016/j.biomaterials.2005.03.036
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
PEGylated trimethyl chitosan (TMC) copolymers were synthesized in an attempt to both increase the solubility of chitosan in water, and improve the biocompatibility of TMC. A series of copolymers with different degrees of substitution were obtained by grafting activated poly(ethylene glycol)s (PEG) of different MW onto TMC via primary amino groups. Structure of the copolymers was characterized using H-1, C-13 NMR spectroscopy and GPC. Solubility experiments demonstrated that PEG-g-TMC copolymers were completely water-soluble over the entire pH range of 1-14 regardless of the PEG MW, even when the graft density was as low as 10%. Using the methyl tetrazolium (MTT) assay, the effect of TMC molecular weight, PEGylation ratio, PEG and TMC molecular weight in the copolymers, and complexation with insulin on the cytotoxicity of TMC was examined, and IC50 values were calculated with L929 cell line. All polymers exhibited a time- and dose-dependent cytotoxic response that increased with molecular weight. PEGylation can decrease the cytotoxicity of TMC to a great extent in the case of low molecular weight TMCs. According to the cytotoxicity results, PEG 5 kDa is superior for PEGylation when compared to PEG 550 Da at similar graft ratios. Complexation with insulin further increased cell viability. In addition, Lactate dehydrogenase (LDH) assays were performed to quantify the membrane-damaging effects of the copolymers, which is in line with the conclusion drawn from MTT assay. Moreover, the safety of the copolymers was corroborated by observing the morphological change of the cells with inverted phase contrast microscopy. Based upon these results PEG-g-TMC merits further investigations as a drug delivery vehicle. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6343 / 6356
页数:14
相关论文
共 38 条
[1]   TOXICITY ASSESSMENT OF PAPAVERINE HYDROCHLORIDE AND PAPAVERINE-DERIVED METABOLITES IN PRIMARY CULTURES OF RAT HEPATOCYTES [J].
DAVILA, JC ;
REDDY, CG ;
DAVIS, PJ ;
ACOSTA, D .
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY, 1990, 26 (05) :515-524
[2]   Poly-L-glutamic acid derivatives as vectors for gene therapy [J].
Dekie, L ;
Toncheva, V ;
Dubruel, P ;
Schacht, EH ;
Barrett, L ;
Seymour, LW .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :187-202
[3]   Effects of different N-trimethyl chitosans on in vitro/in vivo ofloxacin transcorneal permeation [J].
Di Colo, G ;
Burgalassi, S ;
Zambito, Y ;
Monti, D ;
Chetoni, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (11) :2851-2862
[4]  
Ferruti P, 1997, P INT S CONTROL REL, V24, P45
[5]   A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine:: Effect of molecular weight on transfection efficiency and cytotoxicity [J].
Fischer, D ;
Bieber, T ;
Li, YX ;
Elsässer, HP ;
Kissel, T .
PHARMACEUTICAL RESEARCH, 1999, 16 (08) :1273-1279
[6]   In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. [J].
Fischer, D ;
Li, YX ;
Ahlemeyer, B ;
Krieglstein, J ;
Kissel, T .
BIOMATERIALS, 2003, 24 (07) :1121-1131
[7]  
FLORY PJ, 1953, PRINCIPLES POLYM CHE, P69
[8]   Effect of the degree of quaternisation of N-trimethyl chitosan chloride on absorption enhancement:: in vivo evaluation in rat nasal epithelia [J].
Hamman, JH ;
Stander, M ;
Kotzé, AF .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 232 (1-2) :235-242
[9]   N-trimethyl chitosan chloride:: Optimum degree of quaternization for drug absorption enhancement across epithelial cells [J].
Hamman, JH ;
Schultz, CM ;
Kotzé, AF .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2003, 29 (02) :161-172
[10]  
Jansma CA, 2003, STP PHARMA SCI, V13, P63